Sagimet Biosciences SGMT
NASDAQ SGMT
$9.86 +0.13 (+1.28%)
As of: Oct 21, 2026 · 11:14 AM EDT

Sagimet Biosciences (SGMT) Operating Leases (2022 - 2026)

Updated

Sagimet Biosciences (SGMT) posted Operating Leases of $1.86 million for Q2 2026.

Analysis

Sagimet Biosciences (SGMT) Operating Leases (2022 - 2026) Analysis & Trends

At the end of FY2022, Sagimet Biosciences' Operating Leases came in at $78,000.

  • The Q2 2026 figure stands as the lowest quarterly Operating Leases since Q4 2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,129.91 Bn 1,098.50 Bn 19.71 Bn
2 Johnson & Johnson 613.69 Bn 532.22 Bn 17.26 Bn
3 AbbVie 503.05 Bn 476.16 Bn 12.70 Bn
4 Merck 367.72 Bn 322.10 Bn 12.21 Bn
5 Novartis Ag 297.87 Bn 261.86 Bn 11.24 Bn
6 Astrazeneca 261.30 Bn 234.99 Bn 12.86 Bn
7 Amgen 235.86 Bn 191.25 Bn 7.24 Bn
8 Gilead Sciences 190.51 Bn 164.71 Bn 6.22 Bn
9 Pfizer 169.83 Bn 116.48 Bn 10.94 Bn
10 Sagimet Biosciences 524.77 Mn -49.71 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 1.86 Mn
Dec 31, 2022 78,000.00
API Access

Sagimet Biosciences Operating Leases API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=operating-leases&ticker=SGMT&period=max&api_key=YOUR_API_KEY